123例原发韦氏环弥漫大B细胞淋巴瘤临床特征与预后分析
DOI: 10.3971/j.issn.1000-8578.2016.05.013
Keywords: Partial Versus Radical Nephrectomy,Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients,Advance of Prognostic Markers of Cervical Cancer,Correlation of CD68+ Tumor-associated Macrophages Number with Ki-67 Expression and Prognosis of Patients with Primary Hepatocellular Carcinoma,Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Metaanalysis,Metaplastic Carcinoma of Breast with Mesenchymal Differentiation: 28 Cases Report,Predictive Value of C-reactive Protein/Albumin Ratio on Prognosis of Patients with Primary Hepatocellular Carcinoma,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Expression and Clinical Significance of Artemin Protein in Triple-negative and Nontriple-negative Breast Cancer Tissues,Prognosis Factors for Patients with Stage pT3N0M0 Thoracic Esophageal Squamous Cell Carcinoma after Radical Resection,Value of 21-gene Assay in Treatment Decisions for Hormone Receptor-positive Nodepositive Early Breast Cancer
Abstract:
摘要 目的 探讨原发韦氏环弥漫大B细胞淋巴瘤（Waldeyer’s ring diffuse large B-cell lymphoma, WR-DLBCL）的临床特征、预后因素及治疗策略。方法 回顾性分析天津医科大学肿瘤医院2006年1月至2014年6月收治的123例初治原发韦氏环DLBCL患者，对其临床特征、治疗方式及生存情况比较分析，Kaplan-Meier法计算3、5年生存率，Log rank检验单因素分析，Cox比例风险模型多因素分析。结果 123例患者中位年龄为56岁（16~80岁），男72例。Ann Arbor分期：Ⅰ期20例，Ⅱ期63例，Ⅲ期23例，Ⅳ期17例。中位随访54月，3年和5年生存率分别为74.7%和56.3%，早期（Ⅰ/Ⅱ期）患者3年和5年生存率分别为84.2%和69.4%。单因素分析显示：年龄、体质状况、B症状、临床分期、国际预后指数（IPI）、乳酸脱氢酶（LDH）水平、近期疗效是影响预后的主要因素；多因素分析显示：IPI评分和近期疗效为独立预后因素。结论 原发韦氏环DLBCL多为早期，肿瘤负荷较轻，生存率较高，多数可长期生存。IPI评分和近期疗效是独立预后因素
Full-Text
